Latest News and Press Releases

- FDA endorses the overall Phase III plan for tesofensine in obesity, including the filing of an NDA based on 12 months safety and efficacy data - NeuroSearch will now finalise Phase III...

Please find attached the presentation to be held at Aker Solutions ASA's Extraordinary General Meeting today, 8 June 2009 at 09:00 CET in Oslo.   ENDS   For further...

* * * * * * * * * * * * * REDEMPTION AND INTEREST EX-DATE Wed 10.06 - SEB Pank AS * * * * * * * * * * * * * NASDAQ OMX Tallinn Market Services +372 640...

Indre værdi for Alm. Brand Formue A/S. ...

Hermed fremsendes prospektmeddelelse vedrørende ny afdeling Emerging Markets Aktier i Investeringsforeningen Gudme Raaschou. ...

As of 08.06.2009 the following significant changes have taken place in the ownership structure of the companies listed on the NASDAQ OMX Tallinn, compared with the standings disclosed...

Substansvärde 2009-06-05: 55 SEK/aktie Svolders substansvärde var oförändrat med 55 SEK/aktie föregående vecka. Hittills under kalenderåret 2009 har Svolders substansvärde ökat med 45...

Studien är en 2:1 randomiserad, placebokontrollerad, dubbel-blind fas II-studie av 1 mg/dag TASQ  jämfört med placebo. Studien omfattar symptomfria patienter med metastaserad, hormonresistent,...

The study is a 2:1 randomized, placebo-controlled, double-blind Phase II study of 1 mg/day TASQ versus placebo. The study encompasses symptom-free patients with metastatic, hormone-resistant, prostate...

H. Lundbeck A/S (Lundbeck) og Takeda Pharmaceutical Company Limited (Takeda) har i dag sammen offentliggjort hovedresultaterne fra de første tre kliniske undersøgelser i fase III...